Skip to main content
RYTM
NASDAQ Life Sciences

IMCIVREE 获得 CHMP 积极意见，扩大 Rhythm Pharma 在欧洲的肥胖症市场机会

feedReported by Dow Jones Newswires
Sentiment info
Positive
Importance info
8
Price
$83.78
Mkt Cap
$5.778B
52W Low
$45.905
52W High
$122.2
Market data snapshot near publication time

summarizeSummary

Rhythm Pharmaceuticals 已获得药品人用委员会（Committee for Medicinal Products for Human Use，CHMP）的积极意见，批准使用 IMCIVREE（setmelanotide）治疗获得性下丘脑肥胖症患者的肥胖和控制饥饿。这一重要的欧洲监管里程碑是在最近 FDA 批准 IMCIVREE 扩大适应症用于同样的病症在美国之后，这是在 3 月 19 日和 20 日宣布的。积极的 CHMP 意见是获得欧盟营销授权的关键一步，显著扩大了 IMCIVREE 超出美国市场的商业机会。这一发展是公司国际增长战略的重大积极因素。投资者现在应该等待来自欧洲委员会的正式决定，这通常是在 CHMP 积极推荐之后。

在该公告发布时，RYTM的交易价格为$83.78，交易所为NASDAQ，所属行业为Life Sciences，市值约为$57.8亿。 52周交易区间为$45.91至$122.20。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed RYTM - Latest Insights

RYTM
Apr 03, 2026, 3:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Rhythm Pharma Appoints Biotech Veteran Kimberly Popovits to Board, Mathers Resigns
Sentiment: Positive
View Wiseek Article
RYTM
Mar 26, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
9
Rhythm Pharma's IMCIVREE Receives Positive EU Opinion for Hypothalamic Obesity, Expanding Global Market
Sentiment: Positive
View Wiseek Article
RYTM
Mar 26, 2026, 9:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Positive CHMP Opinion for IMCIVREE Expands Rhythm Pharma's European Market Opportunity for Hypothalamic Obesity
Sentiment: Positive
View Wiseek Article
RYTM
Mar 20, 2026, 9:20 AM EDT
Filing Type: 8-K
Importance Score:
9
FDA Approves IMCIVREE for Acquired Hypothalamic Obesity, Expanding Market for First-Ever Therapy
Sentiment: Positive
View Wiseek Article
RYTM
Mar 19, 2026, 6:30 PM EDT
Source: GlobeNewswire
Importance Score:
9
FDA Approves IMCIVREE for Acquired Hypothalamic Obesity, First & Only Therapy for Rare Disease
Sentiment: Positive
View Wiseek Article
RYTM
Mar 16, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Rhythm Pharma's Setmelanotide Phase 3 EMANATE Trial Misses Primary Endpoints, Post Hoc Data Shows Promise
Sentiment: Negative
View Wiseek Article
RYTM
Mar 02, 2026, 6:01 AM EST
Filing Type: 8-K
Importance Score:
8
Rhythm Pharma Reports Strong Additional Phase 3 Data for Setmelanotide in Hypothalamic Obesity Ahead of PDUFA Date
Sentiment: Positive
View Wiseek Article
RYTM
Mar 01, 2026, 12:31 PM EST
Source: Reuters
Importance Score:
9
Setmelanotide Phase 3 Trial Hits Primary Endpoint with 16.4% BMI Reduction; PDUFA Date Set for March 20
Sentiment: Positive
View Wiseek Article
RYTM
Mar 01, 2026, 12:30 PM EST
Source: GlobeNewswire
Importance Score:
9
Expanded Phase 3 Data for Setmelanotide Reveals 18.8% BMI Reduction in Hypothalamic Obesity
Sentiment: Positive
View Wiseek Article
RYTM
Feb 26, 2026, 6:11 PM EST
Source: Reuters
Importance Score:
7
Rhythm Pharmaceuticals Files For Mixed Shelf
Sentiment: Negative
View Wiseek Article